The Alabama Board of Pharmacy is weighing whether to renew a permit for Sun Pharmaceuticals (SUNPHARMA) to distribute its medicines in the state after discovering the company was shipping products after its permit expired nearly two years ago, the latest in a growing number of concerning business practices at one of the world’s largest generic drug makers.

A November hearing is scheduled to review an application that Sun Pharma has filed for a new permit, although ongoing settlement talks are under way, according to James Ward, an attorney who represents the board. He did not respond to a question concerning any penalties that Sun may face for distributing medicines, including a generic version of the oxycodone painkiller, without a permit.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy